Open AccessIn vitro evaluation of A-56619 and A-56620, two new quinolones
Author(s) -
Arthur L. Barry,
C Thornsberry,
Ronald N. Jones
Publication year - 1986
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.29.1.40
Subject(s) - ofloxacin , norfloxacin , enoxacin , ciprofloxacin , fleroxacin , microbiology and biotechnology , antibacterial agent , pseudomonas , anaerobic bacteria , quinolone , chloramphenicol , biology , antibiotics , chemistry , bacteria , genetics
The in vitro activities of two new aryl-fluoroquinolones (A-56619 and A-56620) were compared with those of ciprofloxacin, ofloxacin, enoxacin, and norfloxacin. All six quinolones had broad spectra of antibacterial activity; the streptococci, Pseudomonas maltophilia, and Pseudomonas cepacia were the least susceptible. A-56619, A-56620, and chloramphenicol had similar activity against anaerobic bacteria. With both drugs, a low frequency of resistant variants (less than 10(-8)) was observed. By regression analysis, A-56619 MICs correlated best with ofloxacin MICs and A-56620 was most similar to ciprofloxacin.